FDA

• 

  Tainted Honey Sticking It to Global Investors, Consumers

  By Marlene Y. Satter, AdvisorOne  |  March 28, 2013

  There are many ways investors can get stung on Asian investments—but there can be sweet opportunities, too

• 

  Food Prices Likely to Stay Higher

  By Marlene Y. Satter, AdvisorOne  |  October 5, 2012

  The effects of droughts in the U.S. and Russia that have driven food prices higher are likely to last for the next six months, according to the U.N., and the global food market will be in “short supply mode.”

• Core Competency

  August 23, 2012

  Solid growth and promising research and development pipelines bode well for companies that sell pharmaceutical and related health-care products.

• 

  Fiduciary Debate: What if Doctors Could Act Like Advisors?

  By Bob Clark, AdvisorOne  |  January 16, 2012

  Wherein our intrepid blogger applies the logician's reductio ad absurdum argument to the current debate over applying the fiduciary standard to brokers, or not.

• PlanTools Releases Retirement Plan Expense Benchmark Study

  By Danielle Andrus, AdvisorOne  |  May 3, 2011

  To fully understand whether their costs are "reasonable," plan sponsors must have reliable and accurate data upon which to base their conclusions.

• High Hopes and Altered Genes

  By Kenneth Silber, Research  |  October 1, 2009

  Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...

• Boomers could see lower drug costs via imports

  By Staff Writer  |  March 5, 2009

  In an effort to ease prescription drug costs in the United States - especially for older Americans - four senators introduced legislation yesterday that will...

• Consistent Appreciation

  By Janet Levaux, AdvisorOne  |  January 1, 2009

  Research Total Return Leaders Based on compounded annual price appreciation and dividends for the 10-year period ending Nov. 13, 2008, for stocks trading at or above...

• Healthy Entrance

  By Janet Levaux, AdvisorOne  |  March 1, 2008

  Stocks in health care, including biotech and pharmaceuticals, are poised for higher levels in 2008 - thanks to present valuations, developing pipelines and acquisition horizons,...

• VC the Hard Way

  By James Picerno  |  November 1, 2006

  "I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....